Upfront Briefing
Lilly gave Verve's cholesterol gene-editing story an early read, and the takeaway was simple: one-shot cardiometabolic competition is not getting quieter. Elsewhere, conference season is doing what conference season does — pulling focus forward. ASCO previews put Akeso, Summit and Revolution in the frame, while REGENXBIO, Novartis and Dyne are edging closer to neuromuscular FDA filings.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,473.5 |
0.4% |
9.2% |
| Nasdaq 100 |
29,481.6 |
0.4% |
17.0% |
| Russell 2000 |
2,869.2 |
0.9% |
14.4% |
| Healthcare (XLV) |
149.9 |
1.2% |
(3.6%) |
| Biotech (XBI) |
131.7 |
(0.8%) |
8.4% |
| Nasdaq Biotech (NBI) |
5,891.5 |
(0.2%) |
3.2% |
| Clinical Trials (BBC) |
42.7 |
(1.4%) |
13.6% |
|
- Quiet U.S. tape into the long weekend: Russell led on dovish growth/yield mix and small-cap re-rate (+0.9%), with XLV (+1.2%) outperforming the broader market as defensive flows picked up.
- Biotech split — XBI (-0.8%) and BBC (-1.4%) lagged on idiosyncratic single-stock drag (Biogen/Denali BIIB122 fail still in the tape) even as XLV pharma-heavies held bid.
- Market data: U.S. cash close Friday 22-May-2026; U.S. markets closed Monday 25-May for Memorial Day.
The Big 3
|
1
|
Lilly reports early Verve cholesterol gene-editing data
|
- Lilly reported Phase 1b Heart-2 data for VERVE-102 — a single-shot in vivo PCSK9 base editor — showing up to 62% mean LDL-C reduction and 88% PCSK9 knockdown at the 1.0 mg/kg dose, durable to 18 months, in 35 HeFH/CAD patients. Late-breaking oral at EAS, simultaneously published in NEJM. Phase 2 planned by year-end.
- Why it matters: A clean, on-statin >60% LDL-C drop sustained at 18 months — with no SAEs — clears the efficacy and safety bar Lilly needed post-VERVE-101 hold to take VERVE-102 into Phase 2. Read-through: cardio-metabolic franchise optionality for LLY; renewed pressure on chronic PCSK9 (Repatha, Leqvio), and a higher bar for one-shot competitors (Beam, Tune, Korro).
- Source: STAT More: Fierce; PR
|
|
2
|
ASCO preview spotlights Akeso, Summit and Revolution
|
- ASCO 2026 (29 May–2 Jun, Chicago) previews are firming up: Akeso's HARMONi-6 OS data in 1L squamous NSCLC selected for the Sunday 31 May plenary as a late-breaker, head-to-head vs tislelizumab + chemo. Revolution, BioNTech, Mabwell and Innovent also drop key oncology updates.
- Why it matters: Plenary-selected OS for ivonescimab + chemo is the single biggest competitive read for Summit (SMMT) — positive data validates the PD-1/VEGF bispecific class and tightens commercial setup ahead of the November ivonescimab US PDUFA, with read-across to BNT327, AK112 ex-China economics, and the entire PD-1/VEGF cohort competing with Keytruda.
- Source: BioSpace More: PR
|
| 3 | Muscular dystrophy developers near FDA submissions |
- REGENXBIO (mid-2026 BLA for RGX-202 in DMD, accelerated approval pathway), Avidity/Novartis (del-zota BLA filing this quarter post the ~$12B Avidity acquisition) and Dyne (DYNE-251/zeleciment rostudirsen BLA Q2 2026) all converging on FDA submissions in neuromuscular this summer.
- Why it matters: With Sarepta's Elevidys safety overhang still capping the AAV gene-therapy comp, a clean BLA acceptance for RGX-202 reopens an accelerated-approval window in DMD and de-risks Novartis' ~$12B Avidity rationale. The setup creates a binary calendar through 2H26 — every filing accepted re-rates the cohort; every CRL widens the gap to Capricor's deramiocel decision.
- Source: BioSpace
|
Everything Else that broke
- WuXi Vaccines drug substance facility wins Brazil ANVISA GMP certification for dengue vaccine manufacturing. — PR
- Hansa highlights ConfIdeS Phase 3 late-breaking abstract for oral presentation at ATC 2026. — PR
- Cornerstone Robotics' Sentire surgical system wins CE Mark MDR. — PR
- Novartis previews kidney portfolio data for ERA 2026 Congress. — PR
- Resolution Therapeutics cites positive 4-year MATCH trial data for RMT in liver cirrhosis (University of Edinburgh). — PR
- BioSpace reviews four biopharma targets that have thwarted multiple programs. — BioSpace
- GENFIT outlines broad scientific and strategic presence at EASL Congress 2026. — PR
- Menarini Group previews new ASCO 2026 oncology data. — PR
- BioCentury spotlights ASCO pancreatic cancer innovation beyond KRAS. — BioCentury
- Labiotech: Bayer's 2026 outlook hinges on sales, lawsuits, approvals. — Labiotech
- BioCentury: Europe's next growth fund could help narrow biotech's capital gap. — BioCentury
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- CVC Capital Partners and Groupe Bruxelles Lambert (GBL) launch a €10.7B (~$12.4B) all-cash tender offer for Recordati at €51.29/share (12.9% premium to 25-Mar undisturbed), targeting delisting from Euronext Milan — largest European pharma deal and largest 2026 LBO announced to date. Co-invest syndicate: ADIA's Luxinva, CPP Investments, PSP Europe, StepStone, AlpInvest, MGG Strategic, CapSol and Andrea Recordati. — Bloomberg
VC / Private Financings
- No new biotech venture financings of note in the last 24 hours (US Memorial Day).
IPOs / Follow-Ons
- No new IPO pricings or material follow-ons over the long weekend.
Academic Corner - Updated trends in the global prevalence and burden of mental disorders, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. — Lancet
|
